New portfolio company ProNoxis established
ProNoxis is working with a novel treatment for rheumatoid arthritis based on a novel mechanism.
The product is intended to be an orally administered small molecule drug. ProNoxis stage is pre CD with positive animal efficacy and safety data. During 2009 LU Bio will in two tranches invest SEK 3,0 million and after this hold a position in ProNoxis of 19%.
To read the full press release